| 2004N-0559 - Joint Meeting of the Arthritis Advisory Committee and the Drug Safety and Risk Management Advisory Committee|
|FDA Comment Number :||EC78|
|Submitter :||Dr. James Wood||Date & Time:||02/07/2005 07:02:30|
|Organization :||Harbor Hospital of Baltimore|
| The COX2's have been a mainstay of my practise since released several yrs. ago. Like any med, risk/benefit is a major consideration when prescribing. The marked decrease of GI side effects and events and the one pill dosing are very attractive. Clarification of the true risk with these meds would be very helpful. I seems like a lot of hype without much substance at this time.